PL2970441T3 - POLIPEPTYDY ZAWIERAJĄCE AGLIKOZYLOWANY Fc - Google Patents
POLIPEPTYDY ZAWIERAJĄCE AGLIKOZYLOWANY FcInfo
- Publication number
- PL2970441T3 PL2970441T3 PL14769541T PL14769541T PL2970441T3 PL 2970441 T3 PL2970441 T3 PL 2970441T3 PL 14769541 T PL14769541 T PL 14769541T PL 14769541 T PL14769541 T PL 14769541T PL 2970441 T3 PL2970441 T3 PL 2970441T3
- Authority
- PL
- Poland
- Prior art keywords
- aglycosylated
- polypeptides containing
- polypeptides
- containing aglycosylated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784669P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/028913 WO2014153063A1 (en) | 2013-03-14 | 2014-03-14 | AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES |
| EP14769541.5A EP2970441B1 (en) | 2013-03-14 | 2014-03-14 | AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2970441T3 true PL2970441T3 (pl) | 2019-09-30 |
Family
ID=50680166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14769541T PL2970441T3 (pl) | 2013-03-14 | 2014-03-14 | POLIPEPTYDY ZAWIERAJĄCE AGLIKOZYLOWANY Fc |
| PL14722463T PL2970423T3 (pl) | 2013-03-14 | 2014-03-14 | Muteiny interleukiny-2 do ekspansji regulatorowych komórek t |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14722463T PL2970423T3 (pl) | 2013-03-14 | 2014-03-14 | Muteiny interleukiny-2 do ekspansji regulatorowych komórek t |
Country Status (40)
| Country | Link |
|---|---|
| US (8) | US9546203B2 (pl) |
| EP (2) | EP2970441B1 (pl) |
| JP (6) | JP6450365B2 (pl) |
| KR (5) | KR102219124B1 (pl) |
| CN (2) | CN105143253B (pl) |
| AP (1) | AP2015008737A0 (pl) |
| AR (1) | AR095541A1 (pl) |
| AU (2) | AU2014236316B2 (pl) |
| BR (1) | BR112015022440B1 (pl) |
| CA (3) | CA2906708C (pl) |
| CL (2) | CL2015002669A1 (pl) |
| CR (2) | CR20200004A (pl) |
| CY (2) | CY1121767T1 (pl) |
| DK (2) | DK2970423T3 (pl) |
| EA (2) | EA032863B1 (pl) |
| ES (2) | ES2720225T3 (pl) |
| HR (2) | HRP20191075T1 (pl) |
| HU (2) | HUE043488T2 (pl) |
| IL (2) | IL241349B (pl) |
| JO (1) | JO3796B1 (pl) |
| LT (2) | LT2970441T (pl) |
| MA (2) | MA38477B1 (pl) |
| ME (2) | ME03482B (pl) |
| MX (2) | MX372880B (pl) |
| MY (2) | MY172991A (pl) |
| NZ (1) | NZ751148A (pl) |
| PE (1) | PE20151763A1 (pl) |
| PH (1) | PH12015502051A1 (pl) |
| PL (2) | PL2970441T3 (pl) |
| PT (2) | PT2970441T (pl) |
| RS (2) | RS58791B1 (pl) |
| SG (2) | SG11201507574VA (pl) |
| SI (2) | SI2970441T1 (pl) |
| SM (2) | SMT201900301T1 (pl) |
| TN (1) | TN2015000416A1 (pl) |
| TR (2) | TR201910802T4 (pl) |
| TW (3) | TWI709572B (pl) |
| UA (1) | UA119140C2 (pl) |
| UY (2) | UY40090A (pl) |
| WO (2) | WO2014153063A1 (pl) |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JP2015532303A (ja) * | 2012-10-04 | 2015-11-09 | ノベルメド セラピューティクス，インコーポレーテッド | 溶血性疾患を治療するための補体第２経路特異的抗体 |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| SG11201507416WA (en) | 2013-03-15 | 2015-10-29 | Amgen Inc | Human pac1 antibodies |
| CA2903587C (en) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| EA201992609A1 (ru) | 2014-02-06 | 2020-03-04 | Ф.Хоффманн-Ля Рош Аг | Слитые белки, содержащие интерлейкин-2, и их применения |
| DK3172227T3 (da) | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| CN113234138A (zh) | 2014-08-11 | 2021-08-10 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体 |
| AU2015318008B2 (en) | 2014-09-15 | 2021-05-20 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
| EP4382535A3 (en) | 2014-12-15 | 2024-08-21 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2016246152A1 (en) * | 2015-04-10 | 2017-11-02 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| MX2018003445A (es) | 2015-09-22 | 2018-08-01 | Genentech Inc | Expresion de proteinas que contienen fc. |
| US10822408B2 (en) | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| IL313507A (en) * | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| IL260920B (en) * | 2016-02-03 | 2022-09-01 | Amgen Res Munich Gmbh | Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof |
| WO2017136818A2 (en) | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| CN107287273B (zh) * | 2016-03-31 | 2021-03-09 | 复旦大学附属妇产科医院 | 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN115073581A (zh) * | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| AU2017281469B2 (en) | 2016-06-22 | 2023-08-31 | David Klatzmann | Genetically modified T lymphocytes |
| WO2018027025A1 (en) * | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| EA201991142A1 (ru) | 2016-11-08 | 2019-10-31 | Варианты il-2 для лечения аутоиммунных заболеваний | |
| EP3551749B1 (en) | 2016-12-07 | 2023-09-27 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| WO2019112852A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111164101B (zh) | 2017-10-04 | 2025-04-25 | 安进公司 | 甲状腺素视黄质运载蛋白免疫球蛋白融合体 |
| PH12020550661A1 (en) | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN118515780A (zh) * | 2017-12-06 | 2024-08-20 | 潘迪恩运营公司 | Il-2突变蛋白及其用途 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| KR102722731B1 (ko) | 2017-12-19 | 2024-10-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
| CA3086842A1 (en) | 2017-12-27 | 2019-07-04 | Kyowa Kirin Co., Ltd. | Il-2 variant |
| AR114080A1 (es) * | 2018-01-12 | 2020-07-22 | Amgen Inc | Anticuerpos pac1 y sus usos |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| US11534479B2 (en) | 2018-02-16 | 2022-12-27 | Iltoo Pharma | Use of interleukin 2 for treating Sjögren's syndrome |
| CN120590539A (zh) * | 2018-03-28 | 2025-09-05 | 百时美施贵宝公司 | 白介素-2/白介素-2受体α融合蛋白以及使用方法 |
| JP7268059B2 (ja) | 2018-06-07 | 2023-05-02 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | アグリコシル化抗体生産用形質転換マウスおよびこれから生産されたアグリコシル化抗体の用途 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112654633B (zh) | 2018-06-22 | 2025-05-09 | 科优基因公司 | 基于细胞因子的可生物活化药物及其使用方法 |
| KR102873899B1 (ko) | 2018-06-22 | 2025-10-20 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
| PE20211091A1 (es) | 2018-07-02 | 2021-06-14 | Amgen Inc | Proteina de union al antigeno anti-steap1 |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| JP7410143B2 (ja) | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| US12350317B2 (en) | 2019-02-08 | 2025-07-08 | The Uab Research Foundation | Immunotherapy for the treatment and prevention of inflammatory bowel disease |
| CA3129834A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
| CN113661175A (zh) | 2019-02-15 | 2021-11-16 | 整体分子公司 | 包含共同轻链的抗体及其用途 |
| CN114126637A (zh) | 2019-03-29 | 2022-03-01 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| CN111944036B (zh) * | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
| US20220227888A1 (en) | 2019-06-07 | 2022-07-21 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
| CA3140208A1 (en) | 2019-07-08 | 2021-01-14 | Amgen Inc. | Multispecific transthyretin immunoglobulin fusions |
| MX2022001061A (es) * | 2019-07-26 | 2022-02-14 | Visterra Inc | Agentes de interleuquina-2 y usos de los mismos. |
| US20220306714A1 (en) * | 2019-08-12 | 2022-09-29 | AskGene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| UY38836A (es) * | 2019-08-13 | 2021-02-26 | Amgen Inc | Muteínas de interleucina-2 para la expansión de células t reguladoras |
| WO2021049606A1 (ja) | 2019-09-13 | 2021-03-18 | 協和キリン株式会社 | ＤｃＲ３改変体 |
| CA3154710A1 (en) | 2019-10-04 | 2021-04-08 | TAE Life Sciences | Antibody compositions comprising fc mutations and site-specific conjugation properties |
| BR112022009521A2 (pt) * | 2019-11-20 | 2022-08-16 | Gi Cell Inc | Composição de meio para cultura de células t e método para cultura de células t usando a mesma |
| EP4048296A4 (en) * | 2019-11-29 | 2024-01-24 | Nkmax Co., Ltd. | METHOD FOR PRODUCING NATURAL KILLER CELLS AND COMPOSITIONS THEREOF |
| US20230036793A1 (en) | 2019-12-12 | 2023-02-02 | Iltoo Pharma | Interleukin 2 chimeric constructs |
| BR112022011949A2 (pt) | 2019-12-17 | 2022-11-22 | Amgen Inc | Dupla de interleucina-2/agonista do receptor tnf para uso em terapia |
| US20210188934A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| JP7303391B2 (ja) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | バイアス型ｉｌ２ムテイン、方法、および組成物 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| CN115698052A (zh) * | 2020-03-19 | 2023-02-03 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
| KR20220155317A (ko) * | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
| CA3171795A1 (en) * | 2020-04-06 | 2021-10-14 | Jintang DU | Modular synthetic receptors and methods of use |
| EP4149554A4 (en) | 2020-05-13 | 2024-05-29 | Bonum Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| US20230203198A1 (en) | 2020-06-04 | 2023-06-29 | Amgen Inc. | Bispecific binding constructs |
| WO2021253360A1 (en) * | 2020-06-18 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| CN112048018B (zh) * | 2020-08-31 | 2021-10-08 | 南方医科大学 | 一种嵌合t细胞生长因子及其应用 |
| MX2023002648A (es) | 2020-09-04 | 2023-04-05 | Shandong Simcere Biopharmaceutical Co Ltd | Mutante de il-2 y aplicacion de este. |
| EP4236962A1 (en) | 2020-10-29 | 2023-09-06 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| AU2021393456A1 (en) | 2020-12-03 | 2023-06-29 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| AU2021391924A1 (en) | 2020-12-04 | 2023-06-22 | The General Hospital Corporation | Methods of using interleukin-2 agents |
| TW202237631A (zh) * | 2020-12-10 | 2022-10-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 用於啟動人類ＩＬ－１０Ｒａ受體的免疫細胞因數及其用途 |
| TW202241932A (zh) * | 2020-12-23 | 2022-11-01 | 美商默沙東藥廠 | 用於治療自體免疫及發炎性疾病之il-2突變蛋白 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| AU2022275666A1 (en) | 2021-05-19 | 2023-12-07 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| KR20240015093A (ko) | 2021-05-27 | 2024-02-02 | 사노피 | Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체 |
| EP4370139A4 (en) | 2021-07-14 | 2025-10-15 | Synthekine Inc | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE |
| EP4380970A1 (en) * | 2021-08-06 | 2024-06-12 | Amgen Inc. | Isolation of therapeutic protein |
| JP2024533848A (ja) | 2021-10-06 | 2024-09-12 | イルトゥー・ファルマ | 炎症組織へのターゲティング特異性を備えるインターロイキン２キメラコンストラクト |
| PE20241177A1 (es) | 2021-10-14 | 2024-05-28 | Teneobio Inc | Proteinas de union a la mesotelina y usos de las mismas |
| JP2024539749A (ja) * | 2021-10-14 | 2024-10-29 | ラッティコン （スージョウ） バイオファーマシューティカルズ カンパニー リミテッド | 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用 |
| CN120131911A (zh) * | 2021-12-01 | 2025-06-13 | 威特拉公司 | 使用白细胞介素-2药剂的方法 |
| EP4476250A1 (en) | 2022-02-07 | 2024-12-18 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
| AU2023225012A1 (en) * | 2022-02-22 | 2024-09-12 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| AU2023227283A1 (en) * | 2022-03-03 | 2024-09-19 | Hainan Simcere Pharmaceutical Co., Ltd. | Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereof |
| EP4499846A1 (en) | 2022-03-25 | 2025-02-05 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| JP2025524899A (ja) | 2022-07-27 | 2025-08-01 | テネオバイオ， インコーポレイテッド | メソテリン結合タンパク質及びその使用 |
| WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
| AU2023356984A1 (en) | 2022-10-05 | 2025-03-20 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| CN120112549A (zh) | 2022-10-25 | 2025-06-06 | 阿布林克斯有限公司 | 具有增强的效应子功能的糖基工程化Fc变体多肽 |
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| TW202444749A (zh) | 2023-01-09 | 2024-11-16 | 美商奧迪希治療公司 | 抗tnfr2抗原結合蛋白及其用途 |
| AU2024226156A1 (en) | 2023-02-21 | 2025-08-28 | Teneobio, Inc. | C-kit binding proteins, chimeric antigen receptors, and uses thereof |
| TW202523698A (zh) | 2023-07-31 | 2025-06-16 | 法商賽諾菲公司 | 抗ｇｐｒｃ５ｄ抗體及組成物 |
| WO2025049858A1 (en) | 2023-09-01 | 2025-03-06 | Amgen Inc. | Molecules for treatment of cancer |
| WO2025096843A1 (en) | 2023-11-03 | 2025-05-08 | Amgen Inc. | Bispecific molecules |
| WO2025096842A2 (en) | 2023-11-03 | 2025-05-08 | Amgen Inc. | Fibroblast targeting molecules |
| WO2025106529A2 (en) * | 2023-11-14 | 2025-05-22 | Cavalry Biosciences, Inc. | Compositions for targeting muscle cells and uses thereof |
| WO2025133290A1 (en) | 2023-12-21 | 2025-06-26 | Temper Bio | Protein for immune regulation |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| US20250313641A1 (en) | 2024-04-09 | 2025-10-09 | Amgen Inc. | Agonistic anti-il-2rbg heavy-chain antibodies |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025221954A1 (en) | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| WO2025259515A2 (en) | 2024-06-11 | 2025-12-18 | Amgen Inc. | Combination treatment |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1988007054A1 (en) | 1987-03-18 | 1988-09-22 | Research Corporation Limited | Complement-binding peptide |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| CA2062582C (en) | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| FR2752462B1 (fr) | 1996-08-14 | 1998-10-23 | Essilor Int | Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| EP1117815A1 (en) | 1998-09-29 | 2001-07-25 | Pioneer Hi-Bred International Inc. | Mar/sar elements flanking rsyn7-driven construct |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| EP1355942B1 (en) * | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
| WO2002048379A1 (en) | 2000-12-15 | 2002-06-20 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta |
| SG141239A1 (en) | 2001-01-26 | 2008-04-28 | Selexis Sa | Matrix attachment regions and methods for use thereof |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| NZ543292A (en) | 2003-06-12 | 2008-04-30 | Lilly Co Eli | GLP-1 analog fusion proteins |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| JP2007510434A (ja) | 2003-11-12 | 2007-04-26 | シェーリング コーポレイション | 多重遺伝子発現のためのプラスミドシステム |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| PT2650020T (pt) * | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| BRPI0612814A2 (pt) * | 2005-07-11 | 2017-06-20 | Macrogenics Inc | anticorpo, métodos para redução e para tratamento de uma resposta imune prejudicial em um mamífero, proteína de ligação ao cd16a, e, método para redução dos efeitos colaterais de primeira dose em um paciente |
| WO2008112325A2 (en) | 2007-03-15 | 2008-09-18 | Biogen Idec Ma Inc. | Treatment of autoimmune disorders |
| GB0623539D0 (en) | 2006-11-24 | 2007-01-03 | Avidex Ltd | Polypeptides |
| US20090016935A1 (en) | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| CA2749539C (en) * | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
| CN102369291A (zh) * | 2009-01-23 | 2012-03-07 | 比奥根艾迪克Ma公司 | 效应子功能降低的稳定Fc多肽及使用方法 |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| CA2785139A1 (en) * | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| KR102188544B1 (ko) | 2010-11-30 | 2020-12-08 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
| ES2694564T3 (es) * | 2011-02-10 | 2018-12-21 | Roche Glycart Ag | Polipéptidos de interleucina-2 mutantes |
| JP5972915B2 (ja) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Ｆｃ変異体 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| US20150353639A1 (en) | 2012-05-21 | 2015-12-10 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| CA2903587C (en) * | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-03-13 US US14/209,914 patent/US9546203B2/en active Active
- 2014-03-13 US US14/209,699 patent/US9580486B2/en active Active
- 2014-03-14 UY UY0001040090A patent/UY40090A/es active IP Right Grant
- 2014-03-14 EP EP14769541.5A patent/EP2970441B1/en active Active
- 2014-03-14 SG SG11201507574VA patent/SG11201507574VA/en unknown
- 2014-03-14 KR KR1020157027977A patent/KR102219124B1/ko active Active
- 2014-03-14 TR TR2019/10802T patent/TR201910802T4/tr unknown
- 2014-03-14 PL PL14769541T patent/PL2970441T3/pl unknown
- 2014-03-14 AU AU2014236316A patent/AU2014236316B2/en active Active
- 2014-03-14 PT PT14769541T patent/PT2970441T/pt unknown
- 2014-03-14 MA MA38477A patent/MA38477B1/fr unknown
- 2014-03-14 DK DK14722463.8T patent/DK2970423T3/da active
- 2014-03-14 HU HUE14769541A patent/HUE043488T2/hu unknown
- 2014-03-14 MX MX2015012890A patent/MX372880B/es active IP Right Grant
- 2014-03-14 CA CA2906708A patent/CA2906708C/en active Active
- 2014-03-14 CN CN201480014913.7A patent/CN105143253B/zh active Active
- 2014-03-14 JP JP2016502985A patent/JP6450365B2/ja active Active
- 2014-03-14 RS RS20190622A patent/RS58791B1/sr unknown
- 2014-03-14 LT LTEP14769541.5T patent/LT2970441T/lt unknown
- 2014-03-14 SM SM20190301T patent/SMT201900301T1/it unknown
- 2014-03-14 WO PCT/US2014/028913 patent/WO2014153063A1/en not_active Ceased
- 2014-03-14 ME MEP-2019-148A patent/ME03482B/me unknown
- 2014-03-14 MY MYPI2015002295A patent/MY172991A/en unknown
- 2014-03-14 HR HRP20191075TT patent/HRP20191075T1/hr unknown
- 2014-03-14 EP EP14722463.8A patent/EP2970423B1/en active Active
- 2014-03-14 SM SM20190415T patent/SMT201900415T1/it unknown
- 2014-03-14 SG SG11201507420UA patent/SG11201507420UA/en unknown
- 2014-03-14 EA EA201591731A patent/EA032863B1/ru not_active IP Right Cessation
- 2014-03-14 HR HRP20190970TT patent/HRP20190970T1/hr unknown
- 2014-03-14 MY MYPI2018002567A patent/MY202248A/en unknown
- 2014-03-14 ES ES14769541T patent/ES2720225T3/es active Active
- 2014-03-14 DK DK14769541.5T patent/DK2970441T3/da active
- 2014-03-14 KR KR1020227022964A patent/KR20220101009A/ko not_active Ceased
- 2014-03-14 PL PL14722463T patent/PL2970423T3/pl unknown
- 2014-03-14 PE PE2015002007A patent/PE20151763A1/es active IP Right Grant
- 2014-03-14 ES ES14722463T patent/ES2737598T3/es active Active
- 2014-03-14 HU HUE14722463 patent/HUE044321T2/hu unknown
- 2014-03-14 KR KR1020157027041A patent/KR102418771B1/ko active Active
- 2014-03-14 AR ARP140101154A patent/AR095541A1/es active IP Right Grant
- 2014-03-14 AP AP2015008737A patent/AP2015008737A0/xx unknown
- 2014-03-14 SI SI201431137T patent/SI2970441T1/sl unknown
- 2014-03-14 CA CA2905141A patent/CA2905141A1/en active Pending
- 2014-03-14 TW TW108117705A patent/TWI709572B/zh active
- 2014-03-14 RS RS20190688A patent/RS58854B1/sr unknown
- 2014-03-14 WO PCT/US2014/029111 patent/WO2014153111A2/en not_active Ceased
- 2014-03-14 CA CA3149348A patent/CA3149348C/en active Active
- 2014-03-14 ME MEP-2019-162A patent/ME03437B/me unknown
- 2014-03-14 MX MX2015012912A patent/MX366854B/es active IP Right Grant
- 2014-03-14 KR KR1020247040171A patent/KR20250002742A/ko active Pending
- 2014-03-14 UA UAA201509641A patent/UA119140C2/uk unknown
- 2014-03-14 UY UY0001035454A patent/UY35454A/es active IP Right Grant
- 2014-03-14 EA EA201591766A patent/EA034326B1/ru not_active IP Right Cessation
- 2014-03-14 TW TW103109295A patent/TWI687435B/zh active
- 2014-03-14 LT LTEP14722463.8T patent/LT2970423T/lt unknown
- 2014-03-14 SI SI201431252T patent/SI2970423T1/sl unknown
- 2014-03-14 CN CN201480027384.4A patent/CN105358570B/zh active Active
- 2014-03-14 NZ NZ751148A patent/NZ751148A/en unknown
- 2014-03-14 KR KR1020237037995A patent/KR20230157526A/ko not_active Ceased
- 2014-03-14 BR BR112015022440-7A patent/BR112015022440B1/pt active IP Right Grant
- 2014-03-14 TW TW109121895A patent/TWI784288B/zh active
- 2014-03-14 TR TR2019/08362T patent/TR201908362T4/tr unknown
- 2014-03-14 CR CR20200004A patent/CR20200004A/es unknown
- 2014-03-14 PT PT14722463T patent/PT2970423T/pt unknown
- 2014-03-14 JP JP2016502936A patent/JP6480409B2/ja active Active
- 2014-03-14 AU AU2014236281A patent/AU2014236281B2/en active Active
- 2014-03-16 JO JOP/2014/0119A patent/JO3796B1/ar active
-
2015
- 2015-09-09 IL IL241349A patent/IL241349B/en active IP Right Grant
- 2015-09-11 PH PH12015502051A patent/PH12015502051A1/en unknown
- 2015-09-11 TN TN2015000416A patent/TN2015000416A1/en unknown
- 2015-09-14 CL CL2015002669A patent/CL2015002669A1/es unknown
- 2015-09-14 CL CL2015002686A patent/CL2015002686A1/es unknown
- 2015-09-16 IL IL241622A patent/IL241622B/en active IP Right Grant
- 2015-10-09 MA MA49207A patent/MA49207B1/fr unknown
- 2015-10-14 CR CR20150557A patent/CR20150557A/es unknown
-
2016
- 2016-12-06 US US15/371,131 patent/US10093711B2/en active Active
-
2017
- 2017-01-17 US US15/408,281 patent/US9932380B2/en active Active
-
2018
- 2018-02-09 US US15/893,451 patent/US10562950B2/en active Active
- 2018-02-21 US US15/901,705 patent/US10829535B2/en active Active
- 2018-12-06 JP JP2018228769A patent/JP2019058182A/ja active Pending
-
2019
- 2019-05-24 CY CY20191100560T patent/CY1121767T1/el unknown
- 2019-07-22 CY CY20191100775T patent/CY1121823T1/el unknown
-
2020
- 2020-10-05 US US17/063,566 patent/US11976102B2/en active Active
- 2020-10-20 JP JP2020175778A patent/JP7227951B2/ja active Active
-
2023
- 2023-02-10 JP JP2023019024A patent/JP2023053148A/ja active Pending
-
2024
- 2024-04-04 US US18/627,094 patent/US20240327485A1/en active Pending
-
2025
- 2025-01-30 JP JP2025013617A patent/JP2025066162A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE043488T2 (hu) | Aglikozilált Fc-t tartalmazó polipeptidek | |
| IL241085B (en) | Hyperglycosylated binding polypeptides | |
| DK2992104T3 (da) | Fremgangsmåde til ekspression | |
| FI20135168L (fi) | Tekniikoita matkaviestinsovellusten räätälöintiä varten | |
| HUE052125T2 (hu) | Billenõ csukló | |
| LT3030259T (lt) | Peptidai | |
| PL3059239T3 (pl) | Związek bicykliczny zawierający siarkę | |
| DK2976256T3 (da) | Ekstern helikopterredningskapsel | |
| DK2840222T3 (da) | Tætningsliste | |
| FR3006896B1 (fr) | Composition photoprotectrice | |
| FR3014440B1 (fr) | Polypeptides entomotoxiques | |
| TH1401005487B (th) | ฝาครอบส่วนปิดผนึกกันฝุ่น | |
| ES1092109Y (es) | Pendiente | |
| UA30598S (uk) | Кришка | |
| UA28337S (uk) | Кришка | |
| UA28336S (uk) | Кришка | |
| UA28334S (uk) | Кришка | |
| ES1083929Y (es) | Embellecedor empotrable | |
| UA25951S (uk) | Кришка | |
| UA27906S (uk) | Кришка | |
| FI10075U1 (fi) | Peitelevy | |
| UA24475S (uk) | Кришка | |
| FI20135325A7 (fi) | Tiiviste | |
| UA28557S (uk) | Розгортка опакування | |
| UA28563S (uk) | Розгортка опакування |